MarketPeel
Insider Trading Intelligence
Pricing
…
RB

Russell P. Beyer

SABS
CHIEF FINANCIAL OFFICER · SAB BIOTHERAPEUTICS, INC. · CIK 0001889754
FILING MIX · LIFETIME90%/10%
BUYS
9
SELLS
1
TOTAL VALUE
$29.9K
COMPANIES
1
ACTIVE SINCE
Sep 2021
HOLDINGS NOW
275,000
AVG SELL PX
$7.90
TRADE KIND
SHOWING 10 / 10
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Russell P. Beyer, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%-6.24%+1.30%-7.54%-7.54%—
14d1+0.00%+0.10%+2.50%-2.40%-2.40%—
30d1+100.00%-9.00%+2.96%-11.96%-11.96%—
60d1+100.00%-10.53%+3.58%-14.11%-14.11%—
90d1+100.00%-37.73%-3.20%-34.53%-34.53%—
180d1+100.00%-72.80%-5.39%-67.41%-67.41%—
1y1+100.00%-91.92%-14.95%-76.98%-76.98%—
2y1+100.00%-90.29%-6.70%-83.58%-83.58%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SABS · 275,000 shares · as of Mar 14, 2023
068,750137,500206,250275,00020222023SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2022
2022
2022
2022
2023
FLOW · 9 buys / 1 sellsCOVERAGE · 7 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
275,000——275,000Mar 14, 2023Mar 16, 2023 ↗View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
274,875——274,875Sep 13, 2022Sep 15, 2022 ↗View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,000——6,000Mar 16, 2022Mar 18, 2022 ↗View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
110,000——110,000Nov 17, 2021Nov 19, 2021 ↗View →
SABS
SAB BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
278$7.90$2.2K0Oct 26, 2021Nov 16, 2021 ↗View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
129$7.78$1.0K278Oct 25, 2021Nov 16, 2021 ↗View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,475$10.10$25.0K2,475Oct 18, 2021Nov 16, 2021 ↗View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10$10.08$10115Sep 29, 2021Nov 16, 2021 ↗View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5$10.07$505Sep 28, 2021Nov 16, 2021 ↗View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
149$10.08$1.5K149Sep 28, 2021Nov 16, 2021 ↗View →
Other insiders · SABS
Loading peer insiders…
About this filer
CIK 0001889754
ROLE
CHIEF FINANCIAL OFFICER
PRIMARY
SABS
COMPANIES
1
ACTIVE SINCE
Sep 2021
MARKETPEEL · /INSIDER/0001889754DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback